Literature DB >> 23620095

Justification criteria for vertebral fractures: year 2012 revision.

Satoshi Mori1, Satoshi Soen, Hiroshi Hagino, Tetsuo Nakano, Masako Ito, Saeko Fujiwara, Yoshiharu Kato, Yasuaki Tokuhashi, Daisuke Togawa, Naoto Endo, Takeshi Sawaguchi.   

Abstract

Justification Criteria for Vertebral Fractures 2012 version was made based on new clinical findings. Major differences in this version compared to the 1996 version are inclusion of the semiquantitative method (SQ), statements to improve considerations during radiographic analysis, and the need for more detailed evaluation by MRI.

Entities:  

Mesh：

Year:  2013        PMID： 23620095     DOI： 10.1007/s00774-013-0441-1

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN： 0914-8779            Impact factor:   2.626


  4 in total

1.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors:  R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

2.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

3.  Vertebral fracture assessment using a semiquantitative technique.

Authors:  H K Genant; C Y Wu; C van Kuijk; M C Nevitt
Journal:  J Bone Miner Res       Date:  1993-09       Impact factor: 6.741

4.  Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Authors:  Charles H Chesnut; Arne Skag; Claus Christiansen; Robert Recker; Jacob A Stakkestad; Arne Hoiseth; Dieter Felsenberg; Hermann Huss; Jennifer Gilbride; Ralph C Schimmer; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2004-03-29       Impact factor: 6.741
  4 in total
  5 in total

1.  Three-dimensional conditional generative adversarial network-based virtual thin-slice technique for the morphological evaluation of the spine.

Authors:  Atsushi Nakamoto; Masatoshi Hori; Hiromitsu Onishi; Takashi Ota; Hideyuki Fukui; Kazuya Ogawa; Jun Masumoto; Akira Kudo; Yoshiro Kitamura; Shoji Kido; Noriyuki Tomiyama
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

2.  Accuracy of spinal curvature assessed by a computer-assisted device and anthropometric indicators in discriminating vertebral fractures among individuals with back pain.

Authors:  S Mizukami; Y Abe; R Tsujimoto; K Arima; M Kanagae; G Chiba; K Aoyagi
Journal:  Osteoporos Int       Date:  2014-03-14       Impact factor: 4.507

3.  Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.

Authors:  A Sakai; M Ito; T Tomomitsu; H Tsurukami; S Ikeda; F Fukuda; H Mizunuma; T Inoue; H Saito; T Nakamura
Journal:  Osteoporos Int       Date:  2015-01-16       Impact factor: 4.507

4.  A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis.

Authors:  Satoshi Soen; Yuki Arai; Saori Matsuda; Kento Emori; Toshimi Ikezaki; Mitsuharu Osawa
Journal:  Osteoporos Sarcopenia       Date:  2020-11-19

5.  Effect of Teriparatide on Bone Mineral Density and Trabecular Bone Score in Type 2 Diabetic Patients with Osteoporosis: A Retrospective Cohort Study.

Authors:  Chihiro Munekawa; Yoshitaka Hashimoto; Noriyuki Kitagawa; Takafumi Osaka; Masahide Hamaguchi; Michiaki Fukui
Journal:  Medicina (Kaunas)       Date:  2022-03-26       Impact factor: 2.948
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.